AaviGen raises 17 million € in second financing round to advance precision gene therapies for heart failure towards the clinical stage
04-Sep-2023 -
AaviGen GmbH, a preclinical stage biotechnology company focused on the development of curative gene therapies for cardiovascular and cardiopulmonary diseases, announced the completion of its 17M € Series B financing round. Building on AaviGen’s proprietary portfolio of engineered cardiac-specific ...
capsids
cardiovascular diseases
financing
+5